The primary therapeutic utility of Стрепсилс Экспресс is centered on providing supportive relief for acute symptomatic discomfort in the oropharyngeal area. Established indications include the management of conditions such as throat infections, severe sore throats, pharyngitis, and associated symptoms like dysphagia (painful swallowing) in adults and adolescents (over 12 years).

The medication is applied when symptoms create noticeable physiological strain, offering assistance for acute and severe pain and localized irritation. This supportive relief may assist with easing the pain, which contributes to improved comfort during periods of heightened symptoms. The product is relevant for managing symptom clusters associated with minor respiratory complaints. The overall benefit is the provision of symptomatic relief that helps ease the overall symptom burden during acute episodes. The medication may be part of symptomatic management in clinical settings that involve acute or disruptive symptom patterns, such as those related to Postoperative Sore Throat (POST).

---

Quick Fact: Relief for Acute Pain and Dysphagia

Regulatory References

1. HPRA Package Leaflet for Strepsils +Plus Anaesthetic Lozenges

Official Eligibility Profile

Regulatory documents strictly define who can and cannot use the Amylmetacresol, Dichlorobenzyl Alcohol, and Lidocaine combination product (Стрепсилс Экспресс).

Eligibility Status	Populations / Conditions
Approved Use	Adults and adolescents 12 years of age and older
Not Recommended	Children under 12 years; women who are pregnant or breastfeeding (use only under medical supervision)
Contraindicated	Persons with hypersensitivity to any active ingredient (Amylmetacresol, Dichlorobenzyl Alcohol, or Lidocaine) or excipients.
Absolute Contraindications	History of allergy to amide-type local anesthetics; patients with a history of or suspected methaemoglobinaemia; specific hereditary metabolic disorders (e.g., fructose intolerance).

Official labeling establishes the minimum age threshold at 12 years. Use during pregnancy and lactation is classified as not recommended because the safety of the combination product has not been fully established. Contraindications also apply to individuals with certain metabolic conditions or a history of allergy to the anesthetic agent Lidocaine, requiring strict adherence to regulatory guidelines for population eligibility.

The official regulatory profile for Стрепсилс Экспресс centers on the potential for altered plasma exposure of the anesthetic component, Lidocaine, and mandatory administration timing restrictions. The combination product has no formally listed drug-drug contraindications in its official regulatory labeling.

Interactions Affecting Lidocaine Exposure

Co-administration with specific medicinal product classes may increase the systemic exposure and potential toxicity of Lidocaine due to pharmacokinetic interactions involving metabolic enzymes. These interacting agents include:

• CYP3A4 Inhibitors: Medicines such as Itraconazole and Erythromycin may inhibit the metabolic clearance of Lidocaine.
• CYP1A2 Inhibitors: Substances such as Cimetidine and Fluvoxamine may similarly affect Lidocaine's metabolic breakdown.
• Pharmacodynamic Agents: Co-use with Beta Blockers or other Antiarrhythmic Drugs (e.g., Mexiletine) may also result in increased Lidocaine exposure or additive systemic effects.

Other Interaction Constraints

The product's profile also details mandatory timing constraints related to its local anesthetic effect. Ingestion of food or chewing gum must be avoided for at least 60 minutes following the administration of the lozenge or spray. This restriction is required due to the risk of accidental trauma caused by mucosal numbness in the mouth and throat.

Regarding the antiseptic components, Amylmetacresol and Dichlorobenzyl Alcohol are noted in official sources to have no known clinically significant interactions documented with other medicines.

How Стрепсилс Экспресс Works

Interruption of Peripheral Sensory Signaling

The anesthetic mechanism operates by blocking voltage-gated sodium channels (NaV channels) on the surface of sensory nerve endings in the throat tissue. This immediate channel blockade prevents the initiation and transmission of the nerve impulse (action potential), thereby resulting in the physiological change of localized cessation of sensory nerve impulse transmission.

---

Dual-Action Antiseptic and Microbial Disruption

The active antiseptic agents, Amylmetacresol and Dichlorobenzyl Alcohol, exert a microbicidal mechanism through the non-specific disruption of microbial structural integrity, primarily damaging bacterial cell membranes and viral envelopes. This action, which is synergistic between the two components, results in the physiological change of a reduction in the concentration of viable microbes on the mucosal surface.

---

Synergy for Enhanced Nociceptive Signal Modulation

The formula leverages a synergistic mechanistic strategy where all three components—Lidocaine and both antiseptics—contribute to the final nerve blockade effect. Since Amylmetacresol and Dichlorobenzyl Alcohol also inhibit ion channels, their contribution provides an additive effect to the sodium channel blockade, resulting in a rapid and additive effect on the transient interruption of nociceptive signal transmission.

Official Administration Guidelines: Strepsils Express

This section outlines the non-instructional, high-level principles for the use of Стрепсилс Экспресс (Amylmetacresol, Dichlorobenzyl Alcohol, and Lidocaine lozenge), as relevant to the product.

---

Administration Scope and Dosing Regimen

Instruction Entity	General Details
Route of Administration	Oromucosal use, applied topically to the tissues of the mouth and throat.
Standard Dosing Schedule	One lozenge per dose. The standard approach is to use the lowest effective dose for the shortest necessary duration.
Frequency and Maximum Dose	Dosing occurs every 2 hours as required for symptom relief, with a maximum limit of 8 lozenges in any 24-hour period.
Age-Group Rules	Approved for use in adults and children aged 12 years and over. The medicine is not recommended for children under 12 years of age.
Course Duration	The product is restricted to short-term use only. Consultation with a healthcare professional is required if symptoms persist, have not improved, or have worsened after 3 days of use.

---

Procedural and Contextual Specifics

Official Use Procedure:

The lozenge is intended to be sucked slowly in the mouth to ensure proper dissolution and effective delivery of the active ingredients to the mucosal surfaces. Users must adhere strictly to the stated maximum dosage and interval.

Contextual Constraints:

Due to the inclusion of Lidocaine, which acts as a local anesthetic, users are advised to exercise care with eating and drinking after administration to mitigate the risk associated with potential numbness of the tongue or throat. If a dose is missed, the practice is to take the next dose as soon as remembered, if needed, and to not double the dose.

---

Connection to the Overall Use Protocol:

This protocol establishes an oromucosal route for localized action, requiring adherence to a fixed 2-hour minimum interval between doses, alongside a clear maximum daily intake. The entire regimen is defined by a strict 3-day time limit before professional re-evaluation of the condition is necessary.

Research Evidence / Overview of Studies for Стрепсилс Экспресс

Evidence for Use in Acute Sore Throat

Research explored the lozenge in contexts involving throat discomfort often associated with an Upper Respiratory Tract Infection (URTI). The core evidence comes from short-term, single-dose, randomized, double-blind, placebo-controlled trials that were used in research exploring how symptoms change over time. These studies were conducted in trials assessing episodic symptom patterns in adults and adolescents who presented with a defined level of pain. Outcomes related to physical discomfort were monitored, focusing on patient-reported outcomes describing perceived discomfort. Research explored how the time to reporting changes in symptom intensity was measured, as well as measurements of functional outcomes related to difficulty swallowing (dysphagia).

The evidence remains limited, as the core research is based on single-dose administration, meaning the follow-up durations were limited to a few hours. This means that data providing insight into the sustained effects of repeated doses over several days of illness are not extensively documented in the primary efficacy research.

Evidence for Use in Postoperative Throat Irritation

The lozenge was also evaluated in a specialized medical context: research examining Postoperative Sore Throat (POST). The lozenge was observed in specific trials that included adults undergoing elective surgery where a Supraglottic Airway Device (SAD) was used under general anesthesia. Outcomes monitored physiological strain or stress, specifically focusing on the incidence and intensity of POST, as well as difficulty swallowing (dysphagia).

Key limitations exist for this specific context, as the results apply only to the patient populations studied in the surgical setting. The research involved small sample sizes in the individual trials, and the intervention was a single, pre-operative dose, meaning that other dosing regimens relevant to POST are not fully characterized in these studies.

Areas for Future Research and Evidence Gaps

Overall certainty remains low for outcomes beyond the initial hours of administration. The primary research gap relates to the multi-day use of the lozenge, as the evidence base predominantly includes single-dose trials. Data for certain groups, such as those with chronic conditions, remain insufficient. Furthermore, studies focusing on episodes where symptoms become more noticeable rely on sample sizes that were modest in some cases, contributing to the limitation that evidence quality varies across studies.

Key Studies & References

1. Preoperative amylmetacresol and dichlorobenzyl alcohol with lignocaine lozenge reduces postoperative sore throat following general anaesthesia using supraglottic airway devices: A double-blinded, randomised, placebo-controlled trial

Common questions about Стрепсилс Экспресс (FAQ)

Q: How is Strepsils Express different from regular Strepsils?

Official documents describe that this product, Strepsils Express, contains Lidocaine, which acts as a local anesthetic, in addition to the two antiseptic agents typically found in standard lozenges. The official description notes that the addition of Lidocaine is intended to help relieve the sensation of pain in the throat.

Q: How quickly does Strepsils Express start working after dissolving the lozenge?

The medicine is noted to have a rapid onset of action. Studies indicate that the onset of relief from sore throat symptoms has been observed within 1 to 10 minutes after the lozenge is fully dissolved.

Q: How long does the effect of one Strepsils Express lozenge last?

Regulatory administration guidelines mandate that users should not take another dose sooner than the required 2-hour interval. Studies indicate that the duration of the pain-relieving effect may last up to 2 hours.

Q: Can Strepsils Express cause numbness or tingling in the mouth?

Yes, this is described as a potential effect. The local anesthetic component, Lidocaine, may cause the tongue or oral cavity to feel numb. This effect is directly associated with the action of Lidocaine.

Q: Is it safe to consume alcohol while using Strepsils Express?

Official documentation does not mention clinically significant interactions with alcohol. Theoretical interactions involving Lidocaine are generally considered unlikely to be relevant when the drug is used topically and temporarily as directed.

Q: Can Strepsils Express be taken by people with diabetes?

Official documents indicate that each lozenge contains glucose and sucrose. This information is provided so that patients with diabetes mellitus can take this content into account.

Q: Is the use of this drug described for a dry throat?

The primary indication for the product is the symptomatic relief of pain, infection, and inflammation in the throat. Dry throat (oropharyngeal dryness) is not specified as a primary therapeutic indication in the regulatory documents.

Q: Can Strepsils Express be taken for chronic pharyngitis?

The drug is intended for short-term use only, typically not exceeding 3 to 5 days. Official guidance indicates that if chronic symptoms persist, consultation with a healthcare professional is necessary.

Q: Why does Strepsils Express sometimes cause a burning sensation in the throat?

Official product information classifies sensations such as burning as a form of oral discomfort. This effect is associated with the active substances in the lozenge.

Q: Is there information on how the drug affects the throat lining?

The active ingredients are applied locally to the mucosal lining of the mouth and pharynx. Lidocaine's action is to cause numbness to interrupt the pain signal, while the antiseptics disrupt the microbial structure on the mucosal surface.

Q: Is Strepsils Express a painkiller or an anti-inflammatory agent?

In regulatory classification, the product belongs to the category of antiseptics and local anesthetics (pain relievers). The official documents do not list an anti-inflammatory action.

Q: Is Strepsils Express permitted for use during pregnancy?

The safety of the product for use in pregnant women has not been established. Use is generally not recommended, except in cases where a doctor specifically advises and monitors its administration.

Q: Can Strepsils Express be taken by breastfeeding mothers?

Metabolites of Lidocaine are known to pass into human breast milk. However, at the recommended therapeutic doses, no effects are anticipated in breastfed infants. Consultation with a healthcare provider is still recommended.

Q: From what age can children be given Strepsils Express?

The medicine is not recommended for use in children under 12 years of age. This age restriction is defined in regulatory documents due to safety considerations regarding the local anesthetic component, Lidocaine.

Q: What should I do if I accidentally swallow the lozenge instead of dissolving it?

Accidental swallowing may result in a sensation of excessive numbing in the upper digestive tract and could cause gastrointestinal discomfort. Serious effects are generally only observed in the context of high systemic doses (overdose).

Q: May long-term use of Strepsils Express cause any problems?

Official guidance indicates that using the product for a prolonged period (more than 3 to 5 days) should be avoided. Extended exposure increases the risk of systemic absorption of Lidocaine, which could potentially affect the nervous or cardiovascular systems.

Q: Is a doctor's prescription needed to buy Strepsils Express?

The product is generally classified in many regions as either over-the-counter (OTC) or available only through a pharmacist (Pharmacy Only). This classification indicates that the medicine is generally available without a prescription, subject to local regulation.

Q: Does food intake affect the action of Strepsils Express lozenges?

Official documentation cautions users to be careful with eating and drinking after administration due to the risk of numbness (e.g., biting the tongue or cheek). Information on food affecting the drug's pharmacological action or absorption is not specified.

Q: Does the composition contain lactose or gluten?

The lozenges contain very low levels of gluten, derived from wheat starch, and are considered 'gluten-free' for celiac patients. Lactose is not listed among the main excipients in the official documents.

Q: Does Strepsils Express contain an antibiotic?

No. The active substances, Amylmetacresol and Dichlorobenzyl Alcohol, are classified as antiseptics. While they possess antibacterial properties, they are not systemic antibiotics.

Q: Are there restrictions on use for the elderly?

There are no specific restrictions for use in the elderly population. However, regulatory warnings recommend caution when administering the product to elderly patients who are acutely ill or frail, as they may be more sensitive to adverse reactions.

Q: Are interactions between Strepsils Express and herbal supplements described?

Official documents detail interactions with certain medicinal products, such as CYP450 enzyme inhibitors and antiarrhythmic drugs. Interactions with herbal supplements are not specifically mentioned in the official interaction constraints.

Q: Can this drug relieve pain from tonsillitis?

The product is indicated for the symp tomatic relief of pain and infections in the throat. This includes the localized pain that is frequently associated with tonsillitis.

Q: Can Strepsils Express cause drowsiness?

Official product information indicates that the medicine has minimal or negligible influence on the ability to drive or use machinery. Effects on the central nervous system (CNS) are only documented as potential risks in the context of exceeding the recommended dose (overdose).

How to Store and Dispose of Strepsils Express

The storage and disposal of Strepsils Express lozenges must comply strictly with official regulatory conditions to maintain the product's stability and ensure safety.

---

Storage Requirements

Condition	Regulatory Mandate
Temperature	Store below 25 C.
Packaging	Keep the lozenges in the original carton or flow wrap.
Child Safety	Must be stored out of the sight and reach of children.

---

️ Disposal Instructions

Official labeling directs that any unused or expired Strepsils Express must be disposed of according to local regulatory requirements for pharmaceutical waste. The product should not be discarded via household trash or wastewater systems.